Gilead Sciences Oncology: New Hope for People with Cancer
Through approximately 40 active alliances and collaborations, we’re joining forces with some of the most promising oncology companies to access external sources of innovation, pursue next-generation cancer therapies and expand potential indications in our pipeline.
Gilead Sciences
We have a deep, diverse pipeline across Virology, Oncology and Inflammation. More than 18,000 employees at Gilead worldwide work to advance scientific innovation, help ensure our medicines reach those who need it and make a difference in …
Virology, Inflammation, & Oncology Pipeline | Gilead
Aug 8, 2024 · Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, & inflammation. Learn about our pipeline.
Research Scholars Programs in Oncology - Gilead Sciences
Since its launch in 2015, our Research Scholars Programs in Oncology have supported meaningful research by high-caliber emerging investigators to help transform scientific understanding, address knowledge gaps and drive medical breakthroughs.
Gilead Sciences Inc (GILD) Q2 2024 Earnings Call Highlights: …
Oct 9, 2024 · Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and raises full-year guidance. ... Oncology Sales: $841 million, up 15% year ...
Gilead Sciences, Inc. - Gilead and Kite Oncology Demonstrate ...
Nov 3, 2022 · Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
Gilead Sciences Therapeutic Areas: Virology, Oncology
For 35 years, Gilead has discovered, developed and delivered innovative therapies in areas of great unmet need. We helped transform HIV from a fatal disease to one that can be well managed, and we’ve helped cure millions of people with hepatitis C around the world.
Gilead's breast cancer drug gets U.S. FDA approval for third …
Feb 3, 2023 · Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most...
Gilead and Kite Oncology Demonstrate Growing Hematology …
Jun 1, 2023 · Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
Leerink upgrades Gilead stock on promising HIV outlook and oncology …
4 hours ago · Gilead reported a 6% year-over-year rise in total product sales, driven by an 8% rise in sales for its HIV treatment, Biktarvy, and a 23% increase for the oncology drug, Trodelvy.
- Some results have been removed